Abivax S.A. - ABVX
About Gravity Analytica
Recent News
- 10.06.2025 - Abivax Management Call to Discuss Late-Breaking Abstract at UEG Conference
- 10.06.2025 - Abivax Management Call to Discuss Late-Breaking Abstract at UEG Conference
- 10.06.2025 - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
- 10.06.2025 - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
- 10.05.2025 - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
- 10.05.2025 - Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
- 09.29.2025 - Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
- 09.29.2025 - Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
- 09.23.2025 - Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting
- 09.23.2025 - Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting